Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept 8mg in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT07365371Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in polypoidal choroidal vasculopathy (PCV), neovascular age-related macular degeneration (NVAMD), sponsored by Shanghai General Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07365371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365371.